Incidence Rates of Pediatric Central Nervous Tumors Display No Geographical Variation

Dayton Grogan BS^{*1}; Vamsi Reddy BS¹; Christopher Banerjee MD MPH¹; Jennifer Waller PhD³; Theodore Johnson MD, PhD²; Ian Heger MD^{4,5}

Affiliations:

¹ Department of Neurosurgery, Medical College of Georgia, Augusta University, Augusta, GA

² Department of Pediatrics and the Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA

³ Department of Biostatistics and Data Science at Augusta University, Augusta, GA

⁴ Pediatric Neurosurgical Specialists., Medical City Children's Hospital, Dallas, TX

⁵ Department of Neurosurgery, Texas Christian University and University of North Texas Health Science Center School of Medicine, Fort Worth, TX

Corresponding Author:

Ian Heger, M.D.

TCU and UNT School of Medicine

7777 Forest Lane Suite B-455

Dallas, TX, 75230

Phone: 678-588-9319

Email: imheger@hotmail.com

Key words: Pediatric brain tumor, pediatric brain cancer, central nervous system tumor

Abstract

Background: Central nervous system (CNS) tumors affect over 4,600 children throughout the United States each year. Despite recent trends of increasing incidence of pediatric CNS tumors, the understanding of variations in their incidence between different geographical regions remains incomplete.

Methods: Data used in this study was obtained from the Surveillance, Epidemiology, and End Results (SEER) Program. The SEER database and its built-in operation software was used to generate state-specific incidence data for newly diagnosed CNS tumor diagnoses in children ages 0-19 for the years 2001-2014. Results were organized by tumor type and individual states were clustered into nine geographical regions as defined by the United States Census Bureau.

Results: Statistically significant differences were found in the regional incidence of astrocytoma, primitive neuroectodermal tumor (PNET), and the category of unspecified intracranial and intraspinal neoplasms. However, the magnitude of the difference in incidence (ΔI) between specific regions was small, on the order of 0.1 to 0.6 per 100,000 population, representing a nominal 0.05-fold to 0.79-fold change in incidence (ΔI /incidence for comparator region) for astrocytoma and for the category of unspecified intracranial and intraspinal neoplasms, and a larger 3.25-fold to 3.75-fold change in incidence for PNET.

Conclusions: Differences in incidence between geographical regions for certain CNS tumor types met the bar for statistical significance. However, these differences are unlikely to be clinically meaningful due to the small effect size.

Introduction

Tumors of the central nervous system (CNS) present significant morbidity and mortality for affected children in the United States. According to the Central Brain Tumor Registry of the United States (CBTRUS), the incidence of primary malignant and nonmalignant CNS tumors in children and adolescents 0-19 years of age is 5.6 cases per 100,000¹. Collectively, CNS tumors are among the most common childhood malignancies, second only to hematologic malignancies, and are the most common form of pediatric solid organ tumor². CNS tumors also represent 20% of all childhood malignancies and are the leading cause of cancer-related deaths in children ages 0-14³. Furthermore, according to recent CDC reports, childhood cancer deaths are in decline except for pediatric CNS tumors³. Therefore, understanding environmental influences that may impact the risk for developing childhood CNS cancer is critical to devising prevention strategies.

Over the past two decades, the overall reported incidence of pediatric CNS tumors has increased⁴⁻¹⁰. However, it is possible that some of this increase may be artifactual, as improvements in detection capabilities have led to an increase in documented CNS tumor cases¹¹⁻¹⁶. Moreover, changes in histological subtyping of tumors, alterations of registry code assignments, and recording of benign tumors in cancer registries have also impacted overall incidence reports. While such factors are unlikely to account for the entire increment in pediatric CNS tumor incidence, the effects of these systemic factors may complicate the study of environmental exposures that may genuinely impact tumorigenesis. To begin elucidating the contribution of such factors, a publically available cancer registry was used to determine whether incidence rates of pediatric CNS tumors vary by geographical location.

Methods

Data Acquisition

All data utilized in this study was obtained from the Surveillance, Epidemiology, and End Results (SEER) Program. This program supported by the National Cancer Institute provides researchers with analytical tools and methodological capability for analysis of population-based statistics in the United States. The SEER Program comprises a database of cancer incidence and survival information collected from population-based cancer registries accounting for approximately 34.6% of the U.S. population¹⁷. Demographically, the SEER program includes data from a significant proportion of cancer patients in the following racial/ethnic populations: Caucasian (31.9%), African American (30%), Hispanic (44%), American Indian/Alaska Native (49.3%), Asians (57.5%), and Hawaiian/Pacific Islander (68.5%). The SEER database and its built-in operation software was used to generate state-specific incidence data for new CNS tumors diagnoses in children ages 0-19 for the years 2001-2014. For a particular tumor type category, data was withheld if there was not a minimum of 16 cases per year, in order to protect against identification of patients with rare tumor types.

Data Organization

For analyses of differential incidence rates, states were organized into nine geographical regions as defined by the United States Census Bureau (**Table 1**). Incidence values for individual states within each geographical region were averaged based on data from the SEER program, and the mean incidence (with 95% confidence interval) were calculated for each region. Incidence data was subdivided according to CNS tumor type, using the predetermined subgrouping system used by the SEER database.

Statistical Analysis

All statistical analysis was performed using SAS 9.4 and statistical significance was assessed using an alpha level of 0.05. Tumor incidence rates/100,000 within region were determined for each tumor type and sub-type from the SEER program database. To examine differences in incident rates between regions for each tumor type and sub-type, a generalized linear model was used with a negative binomial distribution for the number of incident cases, a log link, and an offset parameter of the log of the pediatric population at risk. A Tukey-Kramer multiple comparison test was used to examine post hoc pairwise differences between regions.

Results

Combined incidence for all pediatric CNS tumors from 2001-2014 were analyzed and plotted onto a map of the United States in order to examine apparent, overarching trends (**Figure 1**). The incidence data was then subdivided into specific CNS tumor types, and heat maps were generated for each tumor subtype (data not shown). Superficial regional differences were indicated by the heat maps for malignant tumors, suggesting an overall higher incidence occurring in the New England and Mid-Atlantic regions.

Further analysis was required to demonstrate which regions may have statistically significant differences in incidence rates of specific CNS tumor types. ANOVA and subsequent pairwise analyses were performed to examine these differences, as summarized in **Table 2**. This analysis revealed statistically significant differences in the regional incidence of astrocytoma ($p=0.0024$), primitive neuroectodermal tumor (PNET, $p=0.0153$), and unspecified intracranial and intraspinal

neoplasms ($p < 0.0001$). However, the magnitude of the difference in incidence (ΔI) between specific regions was small, on the order of 0.1 to 0.6 per 100,000 population, representing a nominal 0.05-fold to 0.79-fold change in incidence (ΔI /incidence for comparator region) for astrocytoma and for unspecified intracranial and intraspinal neoplasms, and a larger 3.25-fold to 3.75-fold change in incidence for PNET.

For astrocytoma, the East North-Central region had significantly higher incidence (2/100,000) than the Mountain ($\Delta I = 0.1/100,000$; 0.05-fold change; $p < 0.0001$), New England ($\Delta I = 0.1/100,000$; 0.05-fold change; $p = 0.0002$), and West North-Central ($\Delta I = 0.2/100,000$; 0.1-fold change; $p = 0.0008$) regions. The East South-Central region had significantly lower incidence (2/100,000) than the Mid-Atlantic region ($\Delta I = 0.4/100,000$; 0.2-fold change; $p = 0.0009$), but significantly higher incidence than the Mountain ($\Delta I = 0.1/100,000$; 0.05-fold change; $p < 0.0001$) region. The Mid-Atlantic region had significantly higher incidence (2.4/100,000) than the Mountain ($\Delta I = 0.5/100,000$; 0.21-fold change; $p < 0.0001$), New England ($\Delta I = 0.3/100,000$; 0.13-fold change; $p < 0.0001$), Pacific ($\Delta I = 0.6/100,000$; 0.25-fold change; $p = 0.0009$), South Atlantic ($\Delta I = 0.4/100,000$; 0.17-fold change; $p = 0.0242$), West North-Central ($\Delta I = 0.2/100,000$; 0.08-fold change; $p < 0.0001$), and West South-Central ($\Delta I = 0.4/100,000$; 0.17-fold change; $p = 0.0015$). The Mountain region had significantly lower incidence (1.9/100,000) than the Pacific ($\Delta I = 0.1/100,000$; 0.05-fold change; $p < 0.0001$), South Atlantic ($\Delta I = 0.1/100,000$; 0.05-fold change; $p < 0.0001$), West North-Central ($\Delta I = 0.3/100,000$; 0.16-fold change; $p = 0.0103$), and West South-Central ($\Delta I = 0.1/100,000$; 0.05-fold change; $p < 0.0001$).

PNET tumors were significantly underrepresented in the West North Central region, which had

significantly lower incidence (0.04/100,000) than the Mid-Atlantic region ($\Delta I=0.13/100,000$; 3.25-fold change; $p=0.0072$) and the Pacific region ($\Delta I=0.15/100,000$; 3.75-fold change; 0.0039).

Regarding unspecified intracranial and intraspinal neoplasms, the West South-Central region had significantly higher incidence (0.38/100,000) than the East North Central ($\Delta I=0.25/100,000$; 0.66-fold change; $p=0.0007$), Mountain ($\Delta I=0.25/100,000$; 0.66-fold change; $p=0.0296$), Pacific ($\Delta I=0.26/100,000$; 0.68-fold change; $p=0.0001$), and West North Central ($\Delta I=0.3/100,000$; 0.79-fold change; $p=0.0071$) regions.

Discussion

Pediatric brain cancer is rare, and one of the pitfalls in examining the geographical distribution of pediatric CNS tumor cases is the overall low incidence compared to the incidence in adult populations.^{1,3} This makes it necessary to analyze a prolonged time period and aggregate state-level data into geographical regions, and makes sub-stratification more difficult for rare tumor types. In our study, spanning the time period between 2001 and 2014, the raw state-level data revealed a trend of higher total pediatric CNS tumor incidence in certain states within the New England and Mid-Atlantic regions, which is similar to results from recent CDC epidemiological studies¹⁸.

Aggregation of state-level data into multi-state geographical regions allowed for statistical analysis to compare incidence rates. No statistically significant difference in the total pediatric CNS tumor incidence was found between the geographical regions. When the incidence data was

stratified according to CNS tumor type, regional differences emerged with statistical significance in the tumor categories of astrocytoma, PNET, and unspecified intracranial and intraspinal neoplasms. However, such statistical differences arise from relatively minor differences between regions. For example, the incidence of astrocytoma for the Mid-Atlantic is slightly higher than the West South Central region, but the actual difference in incidence is 0.4 patients per 100,000 children (**Table 2**), which represents a trivial 0.17-fold difference. Using census-recorded pediatric population data for the Mid-Atlantic region during 2014 (8,939,737) as reference, this would translate into a small absolute difference of approximately 35 patients per year between these two regions. In the PNET category, the West North Central region had incidence rates that were 3.25-fold less than the Mid-Atlantic region and 3.75-fold less than the Pacific region. However, the actual incidence rates were very low (0.04 to 0.15/100,000), thirteen to fifty times lower than the incidence for astrocytoma, which translated to exceedingly low differences in absolute case numbers. Thus, while statistically significant regional differences emerge with stratification of the incidence data by CNS tumor type, the differences are very small and unlikely to be clinically meaningful.

Limitations for this study are related to data collection methods. The low overall incidence of pediatric CNS tumors limits the degree of sub-stratification that can maintain meaningful statistical results. In addition, the data collection methods utilized in the SEER data platform make it difficult to correlate differences in incidence to environmental factors. For instance, it is possible that a patient entered into the registry may have recently moved to that state (region), having spent the majority of their life in another geographical region. To protect patient privacy, incidence data is not reported for tumor types with less than sixteen cases per year, so the current

study is not applicable to very rare pediatric CNS tumor types. Finally, future analyses of clinical registries will be hampered by evolving changes in the World Health Organization (WHO) classification of CNS tumor types, and it may not be possible to re-classify patients already in the database using the newer diagnostic criteria which rely heavily upon genetic analyses of tumors^{19,20}.

Numerous previous studies have found significant regional differences in non-CNS tumors such as pleural mesothelioma, prostate cancer, and hepatocellular carcinoma.²¹⁻²³ Such findings in non-CNS tumors were further correlated with regional and environmental differences in demographic factors such as age, gender, age, ethnicity, diet, *etc.* We speculate that certain pediatric tumors may follow similar trends, especially when considering potential effects of certain maternal environmental exposures.²⁴ However, in this study no clinically meaningful differences were found between geographical regions in the incidence of pediatric CNS tumors, either in aggregate or stratified by CNS tumor type.

References:

1. Ostrom QT, de Blank PM, Kruchko C, et al. Alex's Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. *Neuro-Oncology*. 2015;16(suppl_10):x1-x36.
2. Linabery AM, Ross JA. Trends in childhood cancer incidence in the US (1992–2004). *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 2008;112(2):416-432.
3. Ostrum Q, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. *Neuro Oncol*. 2014;16(S4):iv1-iv63.
4. Blair V, Birch JM. Patterns and temporal trends in the incidence of malignant disease in children: II. Solid tumours of childhood. *European Journal of Cancer*. 1994;30(10):1498-1511.
5. Bunin GR, Feuer EJ, Witmar PA, Meadows AT. Increasing incidence of childhood cancer: report of 20 years experience from the greater Delaware Valley Pediatric Tumor Registry. *Paediatric and perinatal epidemiology*. 1996;10(3):319-338.
6. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the US. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 1996;78(3):532-541.
7. Hjalmar U, Kulldorff M, Wahlqvist Y, Lannering B. Increased incidence rates but no space-time clustering of childhood astrocytoma in Sweden, 1973–1992: A population-based study of pediatric brain tumors. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 1999;85(9):2077-2090.
8. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. *Neuro-Oncology*. 2006;8(1):27-37.
9. McKinney P, Ironside J, Harkness E, Arango J, Doyle D, Black R. Registration quality and descriptive epidemiology of childhood brain tumours in Scotland 1975-90. *Brit J Cancer*. 1994;70(5):973-979.
10. Smith MA, Freidlin B, Gloeckler Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. *JNCI: Journal of the National Cancer Institute*. 1998;90(17):1269-1277.
11. Desmeules M, Mikkelsen T, Mao Y. Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. *JNCI: Journal of the National Cancer Institute*. 1992;84(6):442-445.
12. Legler JM, Ries LAG, Smith MA, et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. *J Natl Cancer I*. 1999;91(16):1382-1390.
13. Mosso ML, Colombo R, Giordano L, Pastore G, Terracini B, Magnani C. Childhood Cancer Registry of the Province of Torino, Italy: Survival, incidence, and mortality over 20 years. *Cancer*. 1992;69(5):1300-1306.
14. Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1995;37(1):67-73.
15. Steinberg EP. The status of MRI in 1986: rates of adoption in the United States and worldwide. *American Journal of Roentgenology*. 1986;147(3):453-455.

16. Steinberg EP, Sisk JE, Locke KE. X-ray CT and magnetic resonance imagers: Diffusion patterns and policy issues. *New Engl J Med*. 1985;313(14):859-864.
17. NC I. Overview of the SEER Program. 2020.
18. Siegel DA, Li J, Henley SJ, et al. Geographic variation in pediatric cancer incidence—United States, 2003–2014. *Morbidity and Mortality Weekly Report*. 2018;67(25):707.
19. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*. 2016;131(6):803-820.
20. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol*. 2021;23(8):1231-1251.
21. Lowry SJ, Weiss NS. Geographic distribution of incidence of pericardial and paratesticular mesotheliomas in the USA. *Cancer Cause Control*. 2016;27(12):1487-1489.
22. Fletcher SA, Marchese M, Cole AP, et al. Geographic distribution of racial differences in prostate cancer mortality. *JAMA network open*. 2020;3(3):e201839-e201839.
23. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007;132(7):2557-2576.
24. Momin A, Grogan D, Carroll W, Linder D, Yu JC. Influenza as a Measure of Maternal Immune Activation and Its Effects on the Incidence of Encephalocele and Microtia. *FACE*. 2020:2732501620973029.

Figures and Tables.

Figure 1. Heat map demonstrating relative trends in regional differences of total incidence reports for pediatric CNS tumors from 2001-2014. Values were determined by dividing the sum of all reported incidence values for all pediatric CNS tumors by the pediatric population (0-19) of each state per 100,000 per year.

Table 1: Regions used in this study with affiliated states.

Region	Associated States
New England	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont
Mid-Atlantic	New Jersey, New York, Pennsylvania
South Atlantic	Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, District of Columbia
East North Central	Illiois, Indiana, Michigan, Ohio, Wisconsin
East South Central	Alabama, Kentcky, Mississippi, Tennessee
West North Central	Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
West South Central	Arkansas, Louisiana, Oklahoma, Texas
Mountain	Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming
Pacific	Alaska, California, Hawaii, Oregon, Washington

Table 2: Incidence rates per 100,000 (95% Confidence Interval) by Region within Tumor Type or Subtype and Generalized Linear Model Test for Differences Between Regions

Tumor Type/Subtype	East North-Central	East South-Central	Mid-Atlantic	Mountain	New England	Pacific	South Atlantic	West North-Central	West South-Central	χ^2	p-value
III CNS and Miscellaneous intracranial and intraspinal neoplasms	5.4 (5.00, 5.8)0	5.5 (4.80, 6.20)	6.4 (5.90, 6.90)	5.3 (4.70, 5.90)	5.6 (4.80, 6.40)	5.3 (4.90, 5.70)	5.6 (5.20, 6.00)	5.6 (5.00, 6.30)	5.7 (5.30, 6.30)	14.87	0.0616
III (a) Ependymomas and choroid plexus tumor	0.42 (0.36, 0.50)	0.41 (0.32, 0.54)	0.47 (0.39, 0.55)	0.46 (0.37, 0.58)	0.48 (0.36, 0.63)	0.44 (0.38, 0.51)	0.42 (0.36, 0.48)	0.46 (0.37, 0.58)	0.46 (0.39, 0.54)	2.28	0.971
III (a.1) Ependymomas	0.32 (0.26, 0.39)	0.32 (0.24, 0.44)	0.36 (0.29, 0.44)	0.36 (0.28, 0.47)	0.35 (0.25, 0.50)	0.32 (0.27, 0.39)	0.32 (0.27, 0.38)	0.35 (0.26, 0.46)	0.37 (0.30, 0.45)	2.36	0.9679
III (a.2) Choroid plexus tumor	0.11 (0.07, 0.16)	0.06 (0.02, 0.14)	0.11 (0.07, 0.17)	0.08 (0.04, 0.15)	0.08 (0.03, 0.19)	0.1 (0.07, 0.15)	0.09 (0.06, 0.13)	0.11 (0.06, 0.20)	0.07 (0.04, 0.12)	4.47	0.8125
III (b) Astrocytoma	2 (1.90, 2.20)	2 (1.80, 2.30)	2.4 (2.20, 2.60)	1.9 (1.70, 2.20)	2.1 (1.80, 2.50)	1.8 (1.70, 2.00)	2 (1.90, 2.20)	2.2 (2.00, 2.50)	2 (1.80, 2.20)	23.84	0.0024
III (c) Intracranial and intraspinal embryonal tumors	0.74 (0.68, 0.80)	0.68 (0.60, 0.78)	0.71 (0.65, 0.78)	0.76 (0.68, 0.85)	0.68 (0.58, 0.79)	0.77 (0.72, 0.83)	0.73 (0.68, 0.78)	0.75 (0.66, 0.84)	0.77 (0.70, 0.83)	5.93	0.6552
III (c.1) Medulloblastomas	0.5 (0.44, 0.56)	0.45 (0.36, 0.55)	0.43 (0.37, 0.50)	0.48 (0.40, 0.58)	0.42 (0.33, 0.54)	0.48 (0.43, 0.55)	0.46 (0.41, 0.52)	0.53 (0.44, 0.64)	0.52 (0.45, 0.59)	6.71	0.5687
III (c.2) PNET	0.16 (0.11, 0.22)	0.11 (0.06, 0.21)	0.17 (0.12, 0.24)	0.08 (0.04, 0.16)	0.04 (0.01, 0.13)	0.19 (0.14, 0.25)	0.14 (0.10, 0.19)	0.04 (0.02, 0.11)	0.12 (0.08, 0.19)	18.92	0.0153
III (c.3) Medulloepithelioma	--	--	--	--	--	--	--	--	--	--	--
III (c.4) Atypical teratoid/rhabdoid tumor	0.07 (0.04, 0.12)	0.09 (0.04, 0.18)	0.09 (0.06, 0.15)	0.08 (0.04, 0.16)	0.05 (0.01, 0.15)	0.09 (0.06, 0.13)	0.1 (0.07, 0.15)	0.06 (0.02, 0.13)	0.11 (0.07, 0.17)	4.33	0.8263
III (d) Other gliomas	0.7 (0.57, 0.84)	0.66 (0.48, 0.91)	0.82 (0.67, 1.00)	0.56 (0.41, 0.76)	0.75 (0.53, 1.10)	0.62 (0.51, 0.75)	0.69 (0.57, 0.82)	0.62 (0.46, 0.85)	0.76 (0.62, 0.93)	7.51	0.4831
III (d.1) Oligodendrogliomas	0.08 (0.05, 0.13)	0.03 (0.01, 0.11)	0.1 (0.06, 0.16)	0.03 (0.01, 0.10)	0.08 (0.03, 0.20)	0.08 (0.05, 0.12)	0.07 (0.04, 0.12)	0.07 (0.03, 0.15)	0.04 (0.02, 0.08)	7.85	0.4483
III (d.2) Mixed and unspecified gliomas	0.6 (0.48, 0.73)	0.59 (0.42, 0.83)	0.7 (0.57, 0.87)	0.46 (0.33, 0.65)	0.65 (0.45, 0.94)	0.53 (0.42, 0.65)	0.58 (0.48, 0.71)	0.51 (0.36, 0.72)	0.69 (0.56, 0.85)	8.53	0.3839
III (d.3) Neuroepithelial glial tumors of uncertain origin	--	--	--	--	--	--	--	--	--	--	--
III (e) Other specified intracranial/intraspinal neoplasms	1.4 (1.20, 1.60)	1.4 (1.10, 1.80)	1.8 (1.60, 2.00)	1.3 (1.10, 1.60)	1.3 (1.00, 1.80)	1.5 (1.30, 1.70)	1.5 (1.30, 1.70)	1.4 (1.10, 1.70)	1.4 (1.20, 1.60)	10.65	0.2222
III (e.1) Pituitary adenomas and carcinomas	0.52 (0.39, 0.69)	0.53 (0.34, 0.84)	0.87 (0.68, 1.10)	0.56 (0.38, 0.84)	0.48 (0.28, 0.84)	0.71 (0.56, 0.90)	0.6 (0.47, 0.76)	0.56 (0.37, 0.85)	0.62 (0.46, 0.82)	11.1	0.1648
III (e.2) Tumors of sellar region (craniopharyngiomas)	0.18 (0.14, 0.24)	0.23 (0.16, 0.35)	0.24 (0.18, 0.31)	0.15 (0.10, 0.24)	0.12 (0.06, 0.23)	0.2 (0.15, 0.26)	0.2 (0.16, 0.26)	0.13 (0.08, 0.22)	0.22 (0.17, 0.29)	9.85	0.276
III (e.3) Pineal parenchymal tumors	0.05 (0.03, 0.08)	--	0.05 (0.03, 0.08)	--	--	0.05 (0.03, 0.08)	0.04 (0.03, 0.07)	--	0.04 (0.02, 0.07)	--	--
III (e.4) Neuronal and mixed neuronal-glial tumors	0.47 (0.39, 0.58)	0.42 (0.30, 0.59)	0.45 (0.36, 0.56)	0.35 (0.25, 0.49)	0.46 (0.31, 0.67)	0.37 (0.30, 0.46)	0.42 (0.34, 0.51)	0.41 (0.30, 0.57)	0.37 (0.28, 0.47)	5.64	0.6876
III (e.5) Meningiomas	0.16 (0.12, 0.22)	0.19 (0.12, 0.29)	0.17 (0.13, 0.24)	0.1 (0.06, 0.18)	0.09 (0.04, 0.20)	0.14 (0.10, 0.19)	0.15 (0.11, 0.20)	0.16 (0.10, 0.25)	0.12 (0.08, 0.18)	6.64	0.5757
III (f) Unspecified intracranial and intraspinal neoplasms	0.13 (0.09, 0.2)	0.2 (0.12, 0.34)	0.21 (0.15, 0.30)	0.13 (0.07, 0.23)	0.11 (0.05, 0.26)	0.12 (0.08, 0.18)	0.21 (0.16, 0.28)	0.08 (0.03, 0.17)	0.38 (0.29, 0.50)	41.91	<0.0001